


Research Activities Newsletter

February & March 2021

In the News: Congratulations to the following awardees!!



Jessica Kruger, Clinical Assistant Professor, Community Health and Health Behavior, is PI on a new award from the Josiah Macy Junior Foundation for the project entitled, *Interprofessional Workforce Development: Scientific Editing Fellowship*. This project will help to build the capacity of the *Journal of Student-Run Clinics* while enhancing the skills of underrepresented students from a variety of health-related professions.



Michael Lamonte, Research Associate Professor, Epidemiology & Environmental Health received a renewal award from the Fred Hutchinson Cancer Research Center/NIH, for the research project entitled, *Physical Activity to Improve CV Health in Older Women: A Pragmatic Trial – DCC*. The project is to collect trial data demonstrating that interventions to prevent clinical events, improve functional status (and independence).



Elizabeth Mietlicki-Baase, Assistant Professor, Exercise and Nutrition Sciences, received a new award from the Foundation for Prader-Willi Research for the research project entitled, *Neurohormonal Controls of Energy Balance in the MAGEL2-deficient Rat*. The project will provide insight into behavioral mechanisms underlying food intake and motivational aspects of feeding in a potential new rodent model of PWS.



Kimberly Naus, Director of CAT Clients Services, received a continuation of the award from the NYS Justice Center for the Protection of People with Special Needs entitled, *Technology-Related Assistance for Individuals with Disabilities (TRAID) Program*. The TRAID program helps people with disabilities access and acquire assistive technology. Consumers are able to use devices on a trial basis to determine the usefulness and need prior to purchase.



Ekaterina Noyes, Professor, Epidemiology and Environmental Health, received a newly transferred award from the University of Rhode Island/NIH for the project entitled, *School-Based Asthma Therapy (SBAT) to Reduce Disparities in Childhood Asthma: Pragmatic Process & Program Implementation Evaluation*. The SBAT program, facilitated by a robust health information exchange (HIE), could serve as a model program to improve asthma care and reduce morbidity for high risk children with asthma.



Tia Palermo, Associate Professor, Epidemiology and Environmental Health, is PI on a new award from Deutsche Gesellschaft fur Internationale Zusammenarbeit GmbH for the research project entitled, *GIZ - Real time monitoring of COVID-19 impacts on Tanzanian youth*. The project will use information from adolescent boys and girls and young people in two Southern Highlands regions on how the COVID-19 outbreak affects them, and how it affects their families and communities. It will inform the design, redirection and implementation arrangements of response measures from the Government of Tanzania.



Guan Yu, Assistant Professor of Biostatistics, received a continuation of the award from the National Cancer Institute/NIH (PIs Yun Wu, Biomedical Engineering and Qiaoqiang Gan, Electrical Engineering), for the research project entitled, *Exosome-Protein-microRNA-OneStop (Exo-PROS) Biosensor: A New Liquid Biopsy for Cancer Screening and Early Detection*. This project will develop the Exo-PROS biosensor into a highly accurate, simple, fast, and cost-effective liquid biopsy test for cancer screening and early detection.

UB successfully renewed its CTSA Award from the National Center for Advancing Translational Sciences for the project entitled, *University at Buffalo Clinical and Translational Science Institute*. The following SPHHP faculty are Co-Investigators (PI: Timothy Murphy, Medicine) on two of the Cores.



Members of the Biostatistics, Epidemiology and Research Design (BERD) Core include: **Michael LaMonte**, Research Associate Professor of Epidemiology & Environmental Health, **Jeffrey Miecznikowski**, Associate Professor of Biostatistics, **Gregory Wilding**, Professor and Chair of Biostatistics and Director of BERD, and **Guan Yu**, Assistant Professor of Biostatistics, The BERD Core offers a range of educational and training opportunities that are responsive to the needs and schedules of faculty, trainees and research staff.



Members of the Team Science Core (TSC) include **Ekaterina Noyes**, Professor of Epidemiology & Environmental Health, Director of the TSC, and **Patricia Ohtake**, Associate Professor of Rehabilitation Science, Co-Director of the TSC. The Team Science Core offers assistance in assembling multidisciplinary clinical research teams by promoting a culture of multidisciplinary collaboration and teamwork, creating opportunities for training and coached experiential learning, and creating a system and metric for assessing team effectiveness and productivity.

Congratulations to all of the SPHHP faculty who were awarded new grants (as PI or Co-I) in University at Buffalo's 2021-2022 Clinical and Translational Science Institute Pilot Studies Program:



Gregory Wilding, Professor and Chair of Biostatistics, is Co-I (PI: Margarita Dubocovich, Pharmacology and Toxicology) for the project entitled, *A Pilot Placebo-Controlled Randomized Double-Blind Trial of Melatonin in Outpatients with COVID-19 Infection*.



Kirkwood Personius, Clinical Associate Professor, Rehabilitation Science received a new award for your project entitled, *Role of NANOG in Improving Function After Peripheral Nerve Injury*.



Jeffrey Miecznikowski, Associate Professor, Biostatistics received a new award for the project entitled, *Classifying Sports-Related Concussions by Symptom Profiles*.



Ekaterina Noyes, Professor, Epidemiology & Environmental Health received a new award (PIs: David Jacobs and Christopher Daly, Pharmacy) for the project entitled, *Examining the Feasibility of a Community Health Worker Program Embedded in Western New York Community Pharmacies to Address Social Determinates of Health*.

Dr. Noyes as PI and **Dr. Wilding** as Co-I also received a new award for the project entitled, *Integration of Cancer Survivorship Into the Rural United States (ICaRUS)*.

In This Issue

In the News: Congratulations to the Following Awardees 1
Grant Clinic..... 4
NIH Funding Opportunities
 Request for Applications (RFA) 6
 Program Announcements Reviews in an Institute (PAR) 8
 Program Announcements (PA) 12
Individual Actions for Sustainability 13

Grant Clinic

NOTICE OF CHANGES TO FUNDING OPPORTUNITIES

[NOT-DA-21-057](#)

Notice of Change to RFA-DA-21-016, "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)"

The purpose of this notice is to inform interested applicants of a change to the Advisory Council Review date to Funding Opportunity Announcement (FOA) [RFA-DA-21-016](#), "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)". **Part 1. Overview Information Key Dates Revised to Read: Advisory Council Review August 2021** All other aspects of this FOA remain unchanged.

[NOT-DA-22-015](#)

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse ([NIDA](#)) will participate, effective immediately in [NOT-MD-21-008](#), Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities".

NOTICE OF INTENT TO PUBLISH

[NOT-AA-21-001](#)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)

The National Institute on Alcohol Abuse and Alcoholism intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for addressing urgent, time-sensitive research questions on the relationships between alcohol consumption/misuse and COVID-19 related outcomes and consequences. The FOA has a due date of April 15, 2021. This FOA will utilize the R01 activity code and clinical trials will not be allowed.

[NOT-AA-21-002](#)

Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trials Not Allowed)

[NOT-AA-21-003](#)

Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)

The National Institute on Alcohol Abuse and Alcoholism intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for addressing urgent, time-sensitive research questions on the relationships between alcohol consumption/misuse and COVID-19 related outcomes and consequences. The FOA is expected to be published in late Winter 2021 with an expected application due date in Spring 2021. Each of these FOAs will utilize the activity codes linked to the notice, and clinical trials will not be allowed.

[NOT-AA-21-004](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Specialized Alcohol Research Centers (P50 Clinical Trial Optional)

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to promote a new initiative by publishing a FOA to solicit applications to develop a broad-based Specialized Alcohol Research Center program to foster and conduct interdisciplinary, collaborative research on alcoholism, alcohol use disorder and the impact of alcohol on health and disease. The FOA is expected to be published in Spring 2021 with an expected application due date in Fall 2021. This FOA will utilize the P50 activity code.

[NOT-AA-21-005](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Comprehensive Alcohol Research Centers (P60 Clinical Trial Optional)

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to develop a broad-based Comprehensive Alcohol Research Center program to foster and conduct interdisciplinary, collaborative research on alcoholism, alcohol use disorder and the impact of alcohol on health and disease. The FOA is expected to be published in Spring 2021 with an expected application due date in Fall 2021. This FOA will utilize the P60 activity code.

NOTICE OF SPECIAL INTEREST

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[OT-AG-21-015](#)

Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

This Notice of Special Interest (NOSI) is to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. **Applicants must include "NOT-AG-21-015" in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-CA-21-031](#)

Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes

The purpose of this Notice of Special Interest is to solicit investigator-initiated applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. Investigations in understudied populations, including those that are medically underserved, are encouraged. This notice applies to due dates on or after *March 8, 2021*, and subsequent receipt dates through January 7, 2024. **Applicants must include "NOT-CA-21-031" in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2024.

[NOT-DA-21-011](#)

Effects of smoking and vaping on the risk and outcome of COVID-19 infection

The purpose of this notice is to communicate NIDA's interest in supporting research on **the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection**. This Notice is a reissuance of [NOT-DA-20-084](#). Research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection are interested. **Applicants must include "NOT-DA-21-011" in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-CA-21-033](#)

Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control

This Notice of Special Interest informs current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries (LMICs), inclusive of upper-middle-income countries, to leverage those partnerships to conduct research on the pandemic's impact on cancer prevention, diagnosis, treatment, and outcomes. Submit applications for this initiative using [PA-20-272](#). **Applicants must include "PA-20-272" in box 4B of the SF424 R&R form. Application Due Date:** March 31, 2021

[NOT-DA-21-017](#)

Medical Consequences of Smoking & Vaping Drugs of Abuse in Individuals with HIV and COVID-19

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. **Applicants must include "NOT-DA-21-017" in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-MD-21-008](#)

Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. Submit applications for this initiative using [PA-20-183](#) & [PA-20-185](#). **Applicants must include "NOT-MD-21-008" in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2022.

[NOT-TR-21-011](#)

Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease Public Health Needs

The National Center for Advancing Translational Sciences ([NCATS](#)) is issuing this notice to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS expects to issue 2-9 awards (anticipated to be \$30,000 to \$60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data. Submit applications for this initiative using [PA-20-272](#). **Applicants must include "NOT-TR-21-011" in box 4B of the SF424 R&R form.** This NOSI will expire on June 02, 2021.

[NOT-CA-21-008](#)

Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data

Through funds available from the [Cancer Moonshot Initiative](#), and pursuant to the National Cancer Institute's (NCI's) interest in advancing data visualization tools and methods for cancer research, applications are invited, through [PA-20-272](#) in conjunction with this Notice of Special Interest (NOSI), for

one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more explorable and interpretable by the broader cancer research community. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “PA-20-272” in box 4B of the SF424 R&R form.** Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022.

NIH Funding Opportunities

NIH Request for Applications (RFAs)

APRIL DUE DATES

[RFA-AA-21-002](#) (R01 Clinical Trial Not Allowed)

[RFA-AA-21-003](#) (R03 Small Research Grants)

[RFA-AA-21-004](#) (R21 Exploratory/Developmental Grants)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use

This FOA will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered.

Application Due Dates: April 14, 2021

MULTIPLE DUE DATES

[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-AG-21-021](#) K76 Clinical Trial Required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

This FOA invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. LOI due 30 days before application due date.

Application Due Dates: October 22, 2021, and October 21, 2022

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our

understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: October 08, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: October 08, 2021, July 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** April 9, 2021, September 8, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

Application Due Dates: Monthly due dates; please refer to the RFA.

[RFA-CA-21-013](#) (R21 Clinical Trial Optional)

[RFA-CA-21-014](#) (U01 Clinical Trial Optional)

[RFA-CA-21-015](#) (U24 Clinical Trial Optional)

[RFA-CA-21-016](#) (U24 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

The purpose of FOA is to invite applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined as initial tool development or the significant modification of existing tools for new applications.

Application Due Dates: June 8, 2021; November 17, 2021

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

Application Due Dates: June 22, 2021; June 22, 2022; June 22, 2023.

[RFA-HL-21-014](#) (R01 – Clinical Trial Optional)

Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus

This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan.

Application Due Dates: October 15, 2021

NIH Program Announcements - Reviews in an Institute (PAR)

[PAR-20-236\(R25\)](#) Clinical Trials Not Allowed

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists

This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This R25 program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance use and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds. **Application Due Dates:** August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022, November 15, 2022, March 15, 2023, August 10, 2023, November 15, 2023

[PAR-20-310 \(R01\)](#) Clinical Trial Optional

Health Services Research on Minority Health and Health Disparities

The primary interest of this FOA is research on system-wide health services research that encompasses the diversity of individuals served within these health care systems. It is expected that projects will include patient or participant samples that are representative of the population served by the health care system(s) to be studied. Projects that include populations that identify across more than one health disparity group are encouraged.

Application Due Dates: November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023.

[PAR-20-302\(R01\)](#)

[PAR-20-303 \(R21\)](#)

Tobacco Control Policies to Promote Health Equity

Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.

Application Due Dates: [Standard dates](#) apply.

[PAR-20-289 \(R25\)](#)-Clinical Trial Not Allowed

NIAID Research Education Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Participants are limited to the following individuals:

- Graduate/health professional (e.g., medical) students, medical residents, postdoctoral fellows, and/or early-career faculty. For this program "early career faculty" must be within the first 8 years of their first faculty appointment.
- Participants may be from a single career stage, or programs may propose to bridge several career stages of participants.
- Participants may be early career researchers that are moving into new research areas relevant to the NIAID research.

Note that high school and undergraduate students, postbaccalaureate fellows, and master's level graduate students may not be supported as participants under this FOA.

Application Due Dates: December 7, 2021; and December 7, 2022

[PAR-21-027 \(R01\)](#) Clinical Trial Not Allowed

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets

This FOA seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Application Due Dates: May 7, 2021, January 7, 2022, May 7, 2022, January 7, 2023.

[PAR-21-044 \(X01\)](#)

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research studies. The PATH Study collects data from adults and youth. Investigators proposing meritorious and feasible studies consistent with [PATH Study objectives](#) and/or research priorities for tobacco regulatory science will be given highest priority for access to PATH Study biospecimens.

Application Due Dates: April 30, 2021, October 29, 2021, April 29, 2022, October 31, 2022, April 28, 2023, October 31, 2023.

[PAR-20-307\(P30\)](#) Clinical Trial Optional

[PAR-20-308\(P30\)](#) Clinical Trial Optional

Developmental AIDS Research Centers on Mental Health and HIV/AIDS

D-ARC awards permit the centralized coordination of affiliated research activities, foster the development of scientific innovations and new collaborations, encourage interdisciplinary research, and facilitate the dissemination of public health advances to implementing agencies, academia, affected communities, and policymakers. These Centers must have the potential to support research over a range of cross-cutting areas that may include biological, biomedical, behavioral, neuroscience, mental health, prevention, clinical sciences, and implementation science research.

Application Due Dates: August 25, 2021, August 25, 2022, and August 25, 2023.

[PAR-21-033](#) (R01 Clinical Trial Required)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis

The purpose of this FOA is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the [NCI DCTD website](#) and/or the [OHAM website](#) to learn more about the various program goals, research priorities, and strategies developed to fight cancer.

Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research;
Application Due Dates: Standard dates apply.

[PAR-21-035](#) (R01 Clinical Trial Required)

Cancer Prevention and Control Clinical Trials Grant Program

The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions.

Application Due Dates: Standard dates apply.

[PAR-21-038](#) (R01 Clinical Trial Not Allowed)

[PAR-21-039](#) (R01 Basic Experimental Studies with Humans Required)

Stephen I. Katz Early Stage Investigator Research Project Grant

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Application Due Dates: May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023

[PAR-21-072](#) (R24 Clinical Trial Not Allowed)

NIAAA Resource-Related Research Projects

The purpose of the R24 grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research.

Application Due Dates: Standard dates apply.

[PAR-21-077](#) (R21/R33 - Clinical Trial Not Allowed)

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections

This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to two additional years of scaled-up, expanded, or confirmatory research support (R33 phase).

Application Due Dates: Standard dates apply

[PAR-20-315](#) R00 Clinical Trial Optional

Limited Competition: Lasker Clinical Research Scholars Transition Award

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Application Due Dates: Rolling receipt dates

[PAR-21-022](#) (R01 Clinical Trial Optional)

[PAR-21-023](#) (R34 Clinical Trial Optional)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services

This FOA seeks research projects that will test implementation strategies intended to achieve system-wide integration of evidence-based practices (interventions, guidelines, or service delivery models) to prevent or treat substance use disorders (broadly defined to include alcohol, tobacco and other drugs, as well as prescription medications). Areas of interest also include implementation of guidelines related to the appropriate use of opioids for pain management in individuals with or at risk for opioid use disorder. When clearly justified, applicants may propose to test strategies that are designed to achieve system-wide de-implementation of programs or clinical practices that are ineffective, unproven, wasteful or harmful.

Application Due Dates: July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023.

[PAR-21-065](#) Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

[PAR-21-066](#) Courses for Skills Development (R25 Clinical Trial Not Allowed)

[PAR-21-067](#) Research Experiences (R25 Clinical Trial Not Allowed)

Cancer Research Education Grants Program

The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Due Dates: Standard dates apply.

[PAR-21-080](#) (R01 Clinical trial not allowed)

[PAR-21-081](#) (R01 Clinical Trial Optional)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations
The purpose of this FOA is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Most research on immigrant health does not consider the factors and processes that pushed migration of members from groups or subsets of groups from one country to another. Little attention has been given to integration of the pre-existing experiences, (for example, starvation resulting from rapid environmental changes, changing food sources, exposures to toxic chemicals and pesticides), and how the experience of migration itself, or how the process of adjustment and adaptation to a new cultural, social, political and ecological environment may affect health outcomes. It is also important to consider the period(s) in the life course when immigration was experienced and how that experience may affect health outcomes.

Application Due Dates: Standard dates apply.

[PAR-21-068](#) (R01 Clinical Trial Optional)

[PAR-21-069](#) (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through

the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.

Application Due Dates: Standard dates apply.

[PAR-21-097](#) (R34 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies.

Application Due Dates: June 17, 2021, October 19, 2021, February 17, 2022, June 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAR-21-098](#) (R61/R33 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials.

Application Due Dates: June 17, 2021, October 19, 2021, February 17, 2022, June 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAS-21-031](#) (R01 Clinical Trial Optional)

Priority HIV/AIDS Research within the Mission of the NIDDK

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#).

Application Due Dates: Standard dates apply.

NIH Program Announcements (PAs)

The following opportunities have standard due dates unless noted otherwise:

[PA-21-164](#)

Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)

Expiration Date: July 18, 2024

[PA-21-151](#)

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Expiration Date: January 08, 2024

[PA-21-071](#)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Expiration Date: May 8, 2023

PA-20-272

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Expiration Date: July 24, 2023

PA-21-047 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)

PA-21-048 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

PA-21-049 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

PA-21-050 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

PA-21-051 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

PA-21-052 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

Expiration Date: September 8, 2023

PA-21-110 Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

Expiration Date: May 08, 2024

Individual Actions for Sustainability

DRIVE LESS



Walk, bike, carpool or take mass transit more often.

You'll save one pound of carbon dioxide for every mile you don't drive!

Visit our website for more information at sphhp.buffalo.edu/ras